Table 2.
Association between baseline Hb levels and clinicopathological characteristics in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
| Characteristics | Before PSM |
After PSM |
||||
|---|---|---|---|---|---|---|
| Hb <110 g/L | Hb ⩾110 g/L | p-value | Hb <110 g/L | Hb ⩾110 g/L | p-value | |
| No. of patients | 102 | 208 | 90 | 165 | ||
| Age, median (range) | 61 (36−91) | 61 (33−85) | 0.60 | 61 (36−91) | 61 (33−85) | 0.37 |
| Sex | ||||||
| Male (%) | 78 (76.5) | 159 (76.4) | 1.00 | 69 (76.7) | 124 (75.2) | 0.63 |
| Smoking history | ||||||
| Yes (%) | 63 (61.8) | 130 (62.5) | 0.90 | 55 (61.1) | 100 (60.6) | 1.00 |
| Histology | ||||||
| Squamous (%) | 34 (33.3) | 79 (38.0) | 0.45 | 29 (32.2) | 53 (32.1) | 1.00 |
| Brain metastasis | ||||||
| Yes (%) | 21 (20.6) | 32 (15.4) | 0.26 | 19 (21.1) | 23 (13.9) | 0.19 |
| Stage | ||||||
| IV (%) | 83 (81.4) | 161 (77.4) | 0.46 | 76 (84.4) | 142 (86.1) | 0.87 |
| ECOG PS | ||||||
| ⩾ 2 (%) | 17 (16.7) | 15 (7.2) | 0.01 | 6 (6.7) | 7 (4.2) | 0.59 |
| Line (%) | 0.01 | 0.20 | ||||
| 1 line | 20 (19.6) | 80 (38.4) | 20 (22.2) | 54 (32.7) | ||
| 2 lines | 45 (44.1) | 64 (30.8) | 38 (42.2) | 58 (35.2) | ||
| ⩾ 3 lines | 37 (36.3) | 64 (30.8) | 32 (35.6) | 53 (32.1) | ||
| Treatment type | ||||||
| Combination (%) | 46 (45.1) | 115 (55.3) | 0.11 | 40 (44.4) | 90 (54.5) | 0.16 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; Hb, hemoglobin; ICI, immune checkpoint inhibitor; PSM, propensity score matching.